Tobacco industry: Problems and policy implementation gaps in India

Regulations by The News Minute
Jun.02.2022
Although there are strict regulations banning or limiting the use and ingredients used in tobacco products, the implementing institution is yet to play a pro-active role in controlling tobacco abuse.

Tobacco production and export is a huge industry in India. According to the Union Finance Minister, as of 2021 the tax revenue from GST, excise duty, compensation cess on tobacco for the last three years stood at Rs 53,750 crore. India is also one of the leading tobacco exporting countries, with exports of leaf tobacco and tobacco products contributing around Rs 6,000 crore annually in terms of foreign exchange to the government. However, little attempt has been made to control and check the abuse in the tobacco industry; tax evasion, illicit tobacco trade and gutka scam have remained a continuous and uncontrolled peril.

The ill-effects of tobacco is not a mystery to us. According to a WHO report, about 1.3 million deaths occur every year due to tobacco-related illness. There are about 273 million tobacco users, and India is the second largest producer and consumer of tobacco globally. Although there are strict tobacco usage and advertisement policies, and health systems to treat tobacco addiction, we have not made substantial progress in recent years.

 

Source:The News Minute

Malaysian Health Minister: Push for Nationwide E-cigarette Ban Underway, Now in Multi-Department Evaluation Stage
Malaysian Health Minister: Push for Nationwide E-cigarette Ban Underway, Now in Multi-Department Evaluation Stage
Malaysian Health Minister Dzulkefly Ahmad announced the government is considering a nationwide e-cigarette ban. A special committee will assess the ban's impact, as some states have already imposed restrictions.
Jul.28 by 2FIRSTS.ai
BAT’s Vuse E-Cigarettes Accused of Misleading Carbon-Neutral Claims in U.S. Class Action Lawsuit
BAT’s Vuse E-Cigarettes Accused of Misleading Carbon-Neutral Claims in U.S. Class Action Lawsuit
British American Tobacco (BAT) and its subsidiary RJ Reynolds are facing a class action lawsuit in California over claims that their Vuse e-cigarette brand misled consumers with false carbon-neutral marketing. Vuse was promoted as “the world’s first carbon-neutral vape brand,” but many of the carbon credits used were found to have no real climate benefit. Consumers are seeking $5 million in damages.
Jun.05 by 2FIRSTS.ai
Philippines Seizes $70,000 Worth of Illegal E-Cigarettes Involving Black Elite Products
Philippines Seizes $70,000 Worth of Illegal E-Cigarettes Involving Black Elite Products
The Philippine National Bureau of Investigation (NBI) seized unregistered e-cigarette products worth PHP 3.9 million (around $70,000) in Cavite and arrested two suspects. The products were found to be in violation of multiple provisions of the country’s Vape Regulation Law (RA 11900).
Jul.04 by 2FIRSTS.ai
Altria Q2 2025: E-cigarette Unit Posts $108M Operating Loss; Nicotine Pouch on! Grows 26.5%
Altria Q2 2025: E-cigarette Unit Posts $108M Operating Loss; Nicotine Pouch on! Grows 26.5%
OCHA Group 2025 disclosed on July 30, 2025, Q2 net income of $6.102 billion, down 1.7% year-over-year, and adjusted diluted EPS of $1.44, up 8.3% year-over-year, while first-half net income of $11.361 billion was down 3.6% year-over-year, and adjusted diluted EPS of $2.67, up 7.2% year-over-year.
Jul.31 by 2FIRSTS.ai
Malaysia’s Council of Rulers Reviews Proposal for Full E-Cigarette Sales Ban
Malaysia’s Council of Rulers Reviews Proposal for Full E-Cigarette Sales Ban
Malaysia’s 269th Conference of Rulers, held on July 16 at the National Palace, discussed national security, judicial appointments, and a proposed nationwide e-cigarette ban. Chaired by Selangor’s Sultan Sharafuddin Idris Shah, the meeting reviewed security briefings and court appointments while noting the vaping ban proposal.
Jul.17 by 2FIRSTS.ai
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
The FDA has launched the Commissioner’s National Priority Voucher (CNPV) program, reducing the review time for certain drugs to as little as 1–2 months. While the program currently applies only to pharmaceuticals, it demonstrates the FDA’s capacity to reform its review pathways. Whether a similar mechanism could extend to tobacco products now appears to be a matter of timing and technical details.
Jun.18